REGNÂ – Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.REGN
$558.87Name : Regeneron Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $59,232,952,320.00
EPSttm : 39.68
Regeneron Pharmaceuticals, Inc.
$558.87
2.46%$13.41Float Short %
1.99
Margin Of Safety %
40
Put/Call OI Ratio
0.74
EPS Next Q Diff
0.93
EPS Last/This Y
-5.46
EPS This/Next Y
4.06
Price
558.87
Target Price
724.95
Analyst Recom
1.71
Performance Q
-5.28
Relative Volume
1.33
Beta
0.33
Ticker: REGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | REGN | 546.88 | 0.75 | 0.68 | 48002 |
| 2025-07-07 | REGN | 536.31 | 0.76 | 1.49 | 46841 |
| 2025-07-08 | REGN | 547.75 | 0.77 | 0.99 | 47152 |
| 2025-07-09 | REGN | 552.58 | 0.77 | 0.24 | 47705 |
| 2025-07-10 | REGN | 559.63 | 0.80 | 0.69 | 47260 |
| 2025-07-11 | REGN | 567.83 | 0.79 | 0.62 | 48301 |
| 2025-07-14 | REGN | 570.78 | 0.79 | 1.47 | 49141 |
| 2025-07-15 | REGN | 548.13 | 0.81 | 2.20 | 50058 |
| 2025-07-16 | REGN | 547.35 | 0.84 | 1.37 | 51489 |
| 2025-07-17 | REGN | 549.97 | 0.84 | 1.83 | 51790 |
| 2025-07-18 | REGN | 542.46 | 0.85 | 0.60 | 52149 |
| 2025-07-21 | REGN | 545.05 | 0.76 | 0.75 | 43977 |
| 2025-07-22 | REGN | 560.92 | 0.76 | 0.96 | 44536 |
| 2025-07-23 | REGN | 572.53 | 0.76 | 0.29 | 44671 |
| 2025-07-24 | REGN | 564.42 | 0.75 | 5.81 | 44899 |
| 2025-07-25 | REGN | 563.22 | 0.76 | 0.57 | 45334 |
| 2025-07-28 | REGN | 558.62 | 0.75 | 1.56 | 44483 |
| 2025-07-29 | REGN | 557.93 | 0.77 | 0.99 | 45278 |
| 2025-07-30 | REGN | 554.81 | 0.78 | 0.25 | 45850 |
| 2025-07-31 | REGN | 545.4 | 0.77 | 0.51 | 46138 |
| 2025-08-01 | REGN | 559.71 | 0.74 | 0.65 | 50255 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | REGN | 547.36 | -25.9 | -1459.0 | 35.45 |
| 2025-07-07 | REGN | 537.97 | -25.9 | -1524.1 | 35.45 |
| 2025-07-08 | REGN | 547.75 | -25.9 | -1385.3 | 35.45 |
| 2025-07-09 | REGN | 552.58 | -25.9 | -1421.4 | 35.45 |
| 2025-07-10 | REGN | 559.76 | -25.9 | -1405.0 | 35.45 |
| 2025-07-11 | REGN | 567.74 | -25.9 | -1348.0 | 35.45 |
| 2025-07-14 | REGN | 570.59 | -25.9 | -1436.5 | 35.45 |
| 2025-07-15 | REGN | 547.96 | -25.9 | -1612.4 | 35.45 |
| 2025-07-16 | REGN | 547.70 | -25.9 | -1107.8 | 35.45 |
| 2025-07-17 | REGN | 550.00 | -25.9 | -1089.3 | 35.45 |
| 2025-07-18 | REGN | 542.39 | -25.9 | -1165.8 | 35.45 |
| 2025-07-21 | REGN | 545.14 | -25.9 | -1084.8 | 35.45 |
| 2025-07-22 | REGN | 561.00 | -25.9 | -982.6 | 35.45 |
| 2025-07-23 | REGN | 572.39 | -25.9 | -1017.3 | 35.45 |
| 2025-07-24 | REGN | 564.64 | -27.2 | -1164.3 | 35.35 |
| 2025-07-25 | REGN | 563.10 | -27.2 | -1189.6 | 35.35 |
| 2025-07-28 | REGN | 558.70 | -27.0 | -1211.2 | 35.44 |
| 2025-07-29 | REGN | 558.15 | -27.0 | -1181.7 | 35.44 |
| 2025-07-30 | REGN | 554.58 | -27.1 | -1205.1 | 35.44 |
| 2025-07-31 | REGN | 545.46 | -27.1 | -1248.0 | 35.44 |
| 2025-08-01 | REGN | 558.87 | -27.1 | -1073.2 | 35.44 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | REGN | 0.00 | 1.02 | 1.95 |
| 2025-07-07 | REGN | 0.00 | 1.03 | 1.95 |
| 2025-07-08 | REGN | 0.00 | 1.03 | 1.95 |
| 2025-07-09 | REGN | 0.00 | 1.03 | 1.95 |
| 2025-07-10 | REGN | 0.00 | 1.03 | 1.95 |
| 2025-07-11 | REGN | 0.00 | 1.03 | 2.16 |
| 2025-07-14 | REGN | 0.00 | 1.55 | 2.16 |
| 2025-07-15 | REGN | 0.00 | 1.55 | 2.16 |
| 2025-07-16 | REGN | 0.00 | 1.55 | 2.16 |
| 2025-07-17 | REGN | 0.00 | 1.55 | 2.16 |
| 2025-07-18 | REGN | 0.00 | 1.55 | 2.16 |
| 2025-07-21 | REGN | 0.00 | 1.05 | 2.16 |
| 2025-07-22 | REGN | 0.00 | 1.05 | 2.16 |
| 2025-07-23 | REGN | 0.00 | 1.05 | 2.16 |
| 2025-07-24 | REGN | 0.00 | 1.05 | 2.16 |
| 2025-07-25 | REGN | 0.00 | 1.05 | 1.99 |
| 2025-07-28 | REGN | 0.00 | -0.30 | 1.99 |
| 2025-07-29 | REGN | 0.00 | -0.30 | 1.99 |
| 2025-07-30 | REGN | 0.00 | -0.30 | 1.99 |
| 2025-07-31 | REGN | 0.00 | -0.30 | 1.99 |
| 2025-08-01 | REGN | 0.00 | -0.30 | 1.99 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
8.22
Avg. EPS Est. Current Quarter
8.57
Avg. EPS Est. Next Quarter
9.15
Insider Transactions
Institutional Transactions
-0.3
Beta
0.33
Average Sales Estimate Current Quarter
3303
Average Sales Estimate Next Quarter
3433
Fair Value
783.62
Quality Score
99
Growth Score
72
Sentiment Score
9
Actual DrawDown %
53.9
Max Drawdown 5-Year %
-59.7
Target Price
724.95
P/E
14.23
Forward P/E
14.03
PEG
11.57
P/S
4.28
P/B
2.06
P/Free Cash Flow
19.45
EPS
39.29
Average EPS Est. Cur. Y​
35.44
EPS Next Y. (Est.)
39.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
31.94
Relative Volume
1.33
Return on Equity vs Sector %
-8.4
Return on Equity vs Industry %
10.2
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
-1073.2
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15182
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading